LBCL-话题@MedSci

#LBCL#

54篇内容 | 977人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2021263, encodeId=4a9b202126339, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=J Clin Oncol：DLBCL患者诊断-治疗间隔时间越短，基础肿瘤负荷可能越高！, objectType=article, longId=210699, objectId=0bbd21069923, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bbd21069923, replyNumber=0, likeNumber=56, createdTime=2021-10-19, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bbd21069923, moduleTitle=J Clin Oncol：DLBCL患者诊断-治疗间隔时间越短，基础肿瘤负荷可能越高！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bbd21069923)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021256, encodeId=f2db202125613, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）, objectType=article, longId=206207, objectId=df2920620e11, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df2920620e11, replyNumber=0, likeNumber=37, createdTime=2021-12-14, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df2920620e11, moduleTitle=YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df2920620e11)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021264, encodeId=6934202126464, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！, objectType=article, longId=211283, objectId=6e722112837b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e722112837b, replyNumber=0, likeNumber=0, createdTime=2022-02-03, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e722112837b, moduleTitle=Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e722112837b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021261, encodeId=bb602021261e3, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤, objectType=article, longId=209158, objectId=40ec209158b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40ec209158b9, replyNumber=0, likeNumber=48, createdTime=2021-06-08, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40ec209158b9, moduleTitle=日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40ec209158b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021257, encodeId=552e202125ee4, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=J Clin Oncol：利妥昔单抗-miniCHOP方案额外加入来那度胺能否进一步提高DLBCL老年患者预后？, objectType=article, longId=206361, objectId=420e206361f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=420e206361f1, replyNumber=0, likeNumber=57, createdTime=2021-05-07, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=420e206361f1, moduleTitle=J Clin Oncol：利妥昔单抗-miniCHOP方案额外加入来那度胺能否进一步提高DLBCL老年患者预后？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=420e206361f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021251, encodeId=63432021251a6, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood：piRNA-30473通过调节m6A RNA甲基化促进DLBCL发生和预后不良, objectType=article, longId=201201, objectId=2be1201201f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2be1201201f5, replyNumber=0, likeNumber=48, createdTime=2021-08-25, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2be1201201f5, moduleTitle=Blood：piRNA-30473通过调节m6A RNA甲基化促进DLBCL发生和预后不良, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2be1201201f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021250, encodeId=9f442021250aa, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood：PET-CT指导性巩固放疗对晚期DLBCL患者长期预后的影响, objectType=article, longId=200532, objectId=ac7a200532c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac7a200532c2, replyNumber=0, likeNumber=30, createdTime=2020-10-13, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac7a200532c2, moduleTitle=Blood：PET-CT指导性巩固放疗对晚期DLBCL患者长期预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac7a200532c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021247, encodeId=6eb9202124eb6, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood：根据基因表达亚群将DLBCL分成新的亚型, objectType=article, longId=187423, objectId=574e18e423b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=574e18e423b2, replyNumber=0, likeNumber=35, createdTime=2020-09-22, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=574e18e423b2, moduleTitle=Blood：根据基因表达亚群将DLBCL分成新的亚型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=574e18e423b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021254, encodeId=01b4202125491, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood：DLBCL患者PET/CT阳性-部分缓解是否足以进行Auto-HCT？, objectType=article, longId=203318, objectId=3485203318ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3485203318ee, replyNumber=0, likeNumber=25, createdTime=2021-02-05, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3485203318ee, moduleTitle=Blood：DLBCL患者PET/CT阳性-部分缓解是否足以进行Auto-HCT？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3485203318ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021253, encodeId=7d0c2021253e3, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood：MYC和BCL2拷贝数变异对DLBCL肿瘤形态的影响及MYC-IHC假阴性的机制, objectType=article, longId=203317, objectId=5a9020331ec1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a9020331ec1, replyNumber=0, likeNumber=20, createdTime=2021-07-05, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a9020331ec1, moduleTitle=Blood：MYC和BCL2拷贝数变异对DLBCL肿瘤形态的影响及MYC-IHC假阴性的机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a9020331ec1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021252, encodeId=f95020212520e, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Ann Hematol：异基因干细胞移植可有效治疗DLBCL, objectType=article, longId=201788, objectId=4e94201e8841, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e94201e8841, replyNumber=0, likeNumber=31, createdTime=2021-01-11, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e94201e8841, moduleTitle=Ann Hematol：异基因干细胞移植可有效治疗DLBCL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e94201e8841)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021243, encodeId=4427202124300, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood：用钙调神经磷酸酶抑制剂治疗DLBCL, objectType=article, longId=184254, objectId=332a184254df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=332a184254df, replyNumber=0, likeNumber=0, createdTime=2020-10-26, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=332a184254df, moduleTitle=Blood：用钙调神经磷酸酶抑制剂治疗DLBCL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=332a184254df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021249, encodeId=93062021249ca, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood：在利妥昔单抗时代，结外DLBCL的临床特征和预后, objectType=article, longId=198980, objectId=03fb1989807e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03fb1989807e, replyNumber=0, likeNumber=40, createdTime=2021-07-17, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03fb1989807e, moduleTitle=Blood：在利妥昔单抗时代，结外DLBCL的临床特征和预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03fb1989807e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021246, encodeId=2db6202124682, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood：Avadomide(CC-122)单药治疗难治性/复发性DLBCL的疗效和安全性, objectType=article, longId=187353, objectId=19ef18e35330, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19ef18e35330, replyNumber=0, likeNumber=41, createdTime=2020-04-08, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19ef18e35330, moduleTitle=Blood：Avadomide(CC-122)单药治疗难治性/复发性DLBCL的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19ef18e35330)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021248, encodeId=8702202124897, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Lancet oncol：R-CHOP联合甲氨蝶呤和鞘内化疗治疗新确诊的IVLBCL的疗效和安全性, objectType=article, longId=190230, objectId=fcd3190230c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcd3190230c9, replyNumber=0, likeNumber=0, createdTime=2021-01-05, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcd3190230c9, moduleTitle=Lancet oncol：R-CHOP联合甲氨蝶呤和鞘内化疗治疗新确诊的IVLBCL的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcd3190230c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021242, encodeId=7afd202124235, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood：不同LBCL亚型间的分子异质性, objectType=article, longId=183342, objectId=0a081833423e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a081833423e, replyNumber=0, likeNumber=24, createdTime=2020-03-27, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a081833423e, moduleTitle=Blood：不同LBCL亚型间的分子异质性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a081833423e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021244, encodeId=87272021244a2, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=tafasitamab一线治疗DLBCL的I期临床研究已正式开展, objectType=article, longId=185457, objectId=3ff918545e72, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ff918545e72, replyNumber=0, likeNumber=39, createdTime=2020-05-12, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ff918545e72, moduleTitle=tafasitamab一线治疗DLBCL的I期临床研究已正式开展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ff918545e72)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021245, encodeId=ba822021245d8, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Blood：高起始总代谢瘤体积有助于鉴别超高危险的DLBCL人群, objectType=article, longId=187114, objectId=435d18e1145d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=435d18e1145d, replyNumber=0, likeNumber=36, createdTime=2020-12-04, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=435d18e1145d, moduleTitle=Blood：高起始总代谢瘤体积有助于鉴别超高危险的DLBCL人群, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=435d18e1145d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021241, encodeId=15582021241eb, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=【2019ASH抢先看】R2-miniCHOP能否改善≥80岁DLBCL患者OS呢？答案可能在你意料之中, objectType=article, longId=182706, objectId=36ab182e0678, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36ab182e0678, replyNumber=0, likeNumber=44, createdTime=2020-09-13, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36ab182e0678, moduleTitle=【2019ASH抢先看】R2-miniCHOP能否改善≥80岁DLBCL患者OS呢？答案可能在你意料之中, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36ab182e0678)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021239, encodeId=acf42021239e3, content=<a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=黄慧强教授：DLBCL 无化疗方案，一项引人关注的尝试, objectType=article, longId=171146, objectId=ca511e114698, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca511e114698, replyNumber=0, likeNumber=27, createdTime=2020-06-07, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca511e114698, moduleTitle=黄慧强教授：DLBCL 无化疗方案，一项引人关注的尝试, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca511e114698)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

LBCL

2020-05-29

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

J Clin Oncol：DLBCL患者诊断-治疗间隔时间越短，基础肿瘤负荷可能越高！

2021-10-19

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）

2021-12-14

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！

2022-02-03

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤

2021-06-08

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

J Clin Oncol：利妥昔单抗-miniCHOP方案额外加入来那度胺能否进一步提高DLBCL老年患者预后？

2021-05-07

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood：piRNA-30473通过调节m6A RNA甲基化促进DLBCL发生和预后不良

2021-08-25

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood：PET-CT指导性巩固放疗对晚期DLBCL患者长期预后的影响

2020-10-13

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood：根据基因表达亚群将DLBCL分成新的亚型

2020-09-22

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood：DLBCL患者PET/CT阳性-部分缓解是否足以进行Auto-HCT？

2021-02-05

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood：MYC和BCL2拷贝数变异对DLBCL肿瘤形态的影响及MYC-IHC假阴性的机制

2021-07-05

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Ann Hematol：异基因干细胞移植可有效治疗DLBCL

2021-01-11

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood：用钙调神经磷酸酶抑制剂治疗DLBCL

2020-10-26

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood：在利妥昔单抗时代，结外DLBCL的临床特征和预后

2021-07-17

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood：Avadomide(CC-122)单药治疗难治性/复发性DLBCL的疗效和安全性

2020-04-08

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Lancet oncol：R-CHOP联合甲氨蝶呤和鞘内化疗治疗新确诊的IVLBCL的疗效和安全性

2021-01-05

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood：不同LBCL亚型间的分子异质性

2020-03-27

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

tafasitamab一线治疗DLBCL的I期临床研究已正式开展

2020-05-12

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

Blood：高起始总代谢瘤体积有助于鉴别超高危险的DLBCL人群

2020-12-04

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

【2019ASH抢先看】R2-miniCHOP能否改善≥80岁DLBCL患者OS呢？答案可能在你意料之中

2020-09-13

ms7258648636991762 (审核中...)

前往app查看评论内容

#LBCL#

黄慧强教授：DLBCL 无化疗方案，一项引人关注的尝试

2020-06-07

科室
- - 订阅+
  - 更多科室
工具
服务